The allergic rhino-conjunctivitis market is experiencing steady growth, driven by the rising prevalence of allergic conditions and increased awareness of effective management options. Advances in treatment, including allergen immunotherapy and targeted biologics, are expanding therapeutic choices and improving patient outcomes. Additionally, the ongoing research and development of novel therapies, such as Immunotek’s MM09, MG01 + T517, and MG56, are expected to sustain long-term market expansion.
LAS VEGAS, Oct. 13, 2025 /PRNewswire/ — DelveInsight’s Allergic Rhino-Conjunctivitis Market Insights report includes a comprehensive understanding of current treatment practices, allergic rhino-conjunctivitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).
DelveInsight Logo
Allergic Rhino-Conjunctivitis Market Summary
The market size for allergic rhino-conjunctivitis in the leading markets is expected to grow significantly by 2034.
The United States accounted for the highest allergic rhino-conjunctivitis treatment market size in 7MM in 2024, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.
Allergic rhino-conjunctivitis, a common chronic inflammatory condition encompassing both allergic rhinitis and allergic conjunctivitis, affects approximately 20% of the global population.
Leading allergic rhino-conjunctivitis companies, such as Immunotek, Merck, ALK-Abello, and others, are active in the allergic rhino-conjunctivitis market.
The promising allergic rhino-conjunctivitis therapies in clinical trials include MM09, MG01 + T517, MG56, and others.
Discover the allergic rhino-conjunctivitis new treatment @ New Treatments for Allergic Rhino-Conjunctivitis
Key Factors Driving the Growth of the Allergic Rhino-Conjunctivitis Market
Rising Prevalence of Allergic Conditions
The global incidence of allergic rhinitis and conjunctivitis is on the rise, influenced by factors such as increased pollution, urbanization, and environmental allergens. These conditions are now more prevalent in both adults and children, leading to a higher demand for effective treatments.
Technological Integration in Treatment Delivery
Innovations in drug delivery systems, such as advanced nasal sprays and ophthalmic formulations, have improved the efficacy and convenience of ARC treatments. These technological advancements enhance patient compliance and satisfaction.
Emergence of Novel Allergic Rhino-Conjunctivitis Drugs
The allergic rhino-conjunctivitis clinical trial landscape is not very robust; only a few drugs are included, such as Immunotek’s MM09, MG01 + T517, and MG56, among others.